Patients featured are compensated by ViiV Healthcare.
What do the studies say?
If you are considering switching treatment or are new to treatment, DOVATO is clinically proven to be as effective as a regimen containing 3 or 4 medicines. See details below.
The effectiveness and safety of DOVATO were determined in 3 clinical studies. Your results may vary.
One study included 741 adults who were already undetectable with their previous HIV treatment.*
369 people switched to DOVATO and 372 people stayed on their previous HIV treatment and were followed for ~3 years.
Less than 1% had a detectable viral load (50 or more copies per mL) with DOVATO or a 3- or 4-drug regimen* at ~ 1 year.
Similar results were seen at ~3 years.
DOVATO WAS PROVEN TO HELP PEOPLE ALREADY ON TREATMENT STAY UNDETECTABLE
as effectively as an HIV regimen containing 3 or 4 medicines.*
Through ~3 years of this study, no patients who switched to DOVATO developed HIV resistance
Results showed that DOVATO works as well as a 3- or 4-drug regimen in diverse groups of adults, regardless of age, sex, race, or CD4 T-cell count.
Side Effects
In this study, 15% of patients taking DOVATO versus 5% taking a 3- or 4-drug regimen* experienced side effects during a ~3-year period. The majority of side effects were mild in severity.
The most common side effects were:
-
Taking DOVATO: weight gain (3%), trouble sleeping (2%), nausea (1%), diarrhea (1%), and anxiety (1%).
- Taking a 3- or 4-drug regimen*: weight gain (2%), nausea (<1%), diarrhea (<1%), and anxiety (<1%).
*Tenofovir alafenamide (TAF)–containing 3- or 4-drug regimen.
PROVEN EFFECTIVE IN PEOPLE NEW TO HIV TREATMENT
Two combined studies included 1,433 adults new to HIV-1 treatment.
716 people started DOVATO and 717 people started a 3-drug HIV treatment† and were followed for ~3 years.
In two combined studies,
DOVATO WAS PROVEN TO HELP PEOPLE NEW TO TREATMENT REACH AND STAY UNDETECTABLE
(less than 50 copies per mL) as effectively as a regimen containing 3 medicines.†
One patient taking DOVATO developed HIV resistance during a ~3-year period.
The majority of people who took DOVATO reached and remained undetectable for ~3 years
Side Effects
Across the two combined studies, 20% of patients taking DOVATO versus 27% taking a 3-drug regimen† experienced side effects over ~3 years.
The most common side effects were:
- Taking DOVATO: headache (3%), nausea (2%), diarrhea (2%), trouble sleeping (2%), tiredness (2%), anxiety (2%), and dizziness (1%).
- Taking a 3-drug regimen†: headache (4%), nausea (6%), diarrhea (3%), trouble sleeping (3%), tiredness (2%), anxiety (<1%), and dizziness (2%).
†Dolutegravir + tenofovir disoproxil fumarate/emtricitabine.
PMUS-DLLWCNT250007